Sunday, 20 September 2026European Markets

CUMULEX Stock 18.34% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with CUMULEX (CLEX.BR) rising 18.34% to €2.00 on Thursday, after three consecutive sessions in a row of losses. BEL 20 fell 0.7% to €3,506.41, after three consecutive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

About CUMULEX

Cumulex N.V. does not have significant operations. Previously, the company was engaged in sugar plantation business in the Democratic Republic of Congo. The company was formerly known as Sucrerie et Raffinerie de l'Afrique Centrale NV and changed its name to Cumulex N.V. in March 2021. The company was founded in 1956 and is based in Diegem, Belgium. Cumulex N.V. is a subsidiary of Value8 NV.

Earnings Per Share

As for profitability, CUMULEX has a trailing twelve months EPS of €-0.23.

Volume

Today's last reported volume for CUMULEX is 15 which is 48.27% below its average volume of 29.

Volatility

CUMULEX's last week, last month's, and last quarter's current intraday variation average was 20.71%, 9.41%, and 34.35%.

CUMULEX's highest amplitude of average volatility was 20.71% (last week), 37.98% (last month), and 34.35% (last quarter).

More news about CUMULEX (CLEX.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com